Immunotherapy Strategies in Advanced Cervical Cancer

Advanced cervical cancer remains a significant global health challenge, with limited survival benefits from conventional therapies. Immunotherapy has emerged as a promising avenue, harnessing the patient’s own immune system to recognise and eradicate malignant cells. Central to this approach are immune checkpoint inhibitors that target key regulatory pathways, notably the programmed cell death protein 1 (PD-1) and its ligand PD-L1, which tumours exploit to evade T-cell attack. Beyond monotherapy, strategies now focus on rational combinations: integrating checkpoint blockade with chemoradiotherapy or anti-angiogenic agents to potentiate antigen release, enhance tumour infiltration by effector cells and remodel immunosuppressive networks. The identification of predictive biomarkers, including PD-L1 expression, tumour-infiltrating lymphocyte density and molecular signatures of immune activation, underpins patient selection and trial design. Emerging work on neoantigen load and co-inhibitory receptors such as CTLA-4, TIM-3 and LAG-3 suggests multi-targeted regimens may overcome adaptive resistance. Collectively, these advances point towards personalised immunotherapy schedules that balance efficacy with manageable toxicity, offering new hope for durable control of metastatic or recurrent cervical carcinoma.

Research from Nature Portfolio

Recent clinical investigation of concurrent chemoradiotherapy with PD-1 blockade has demonstrated encouraging efficacy in locally advanced cases. A phase 1 trial combining nivolumab with definitive chemoradiotherapy reported high objective response rates and a two-year progression-free survival approaching 75 per cent. Immune profiling revealed that responders exhibited a robust intratumoural T-cell infiltrate, enhanced proximity of CD3+ and FOXP3+ cells to PD-L1+ tumour and myeloid populations, and elevated expression of activation markers on effector T-cell subsets. These findings support further evaluation in larger cohorts and highlight the value of pre-existing immune activation as a biomarker for benefit.

Immunotherapy Strategies in Advanced Cervical Cancer publication trend

The graph below shows the total number of articles in immunotherapy strategies in advanced cervical cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Programmed cell death protein 1 (PD-1): Immune checkpoint receptor on T cells that downregulates immune responses when engaged by its ligands.

Programmed death-ligand 1 (PD-L1): Ligand for PD-1 expressed by tumour and immune cells to inhibit T-cell activity.

Immune checkpoint inhibitor: Therapeutic antibody that blocks inhibitory receptor–ligand interactions to restore antitumour immunity.

Tumour-infiltrating lymphocytes (TILs): Immune cells, especially T cells, that have migrated into the tumour microenvironment.

References

1. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nature Communications (2023).
2. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of Clinical Oncology (2020).
3. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology (2021).
4. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integrative Cancer Science and Therapeutics (2018).